Helix identifies lead product candidate from DOS47 cancer therapeutic program
L-DOS47 uses an antibody developed by the Institute for Biological Sciences of the National Research Council of Canada (NRC-IBS) to target cancerous tissues of the lung. The antibody is highly specific for adenocarcinoma of the lung with minimal cross reactivity to other tissues based on preliminary histological studies. The Company also has completed studies showing the ability of L-DOS47 to bind cancer cells in vitro and kill cancer cells based on DOS47's theorized mechanism of action of local pH elevation and ammonia production.
Helix has entered into a worldwide exclusive license with NRC-IBS to develop L-DOS47 as a potential human therapeutic. The license calls for an upfront fee and certain milestone payments at clinical stages. Helix also has rights to use the antibody to develop future DOS47 related products.
Moving forward, Helix has commenced a formal pharmaceutical development program for L-DOS47, with the ultimate goal of conducting clinical trials in patients with adenocarcinoma of the lung. In order to complete this work, the Company continues to seek the necessary financing to support its objectives.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.